Discover personalized drug opportunity and optimized tumor-infiltrating lymphocyte therapy for rare cancer: an organoid-based whole-journey clinical mapping study in a neuroendocrine cancer patient

Sep 22, 2026

Upload by Riley

Rare cancer patients face poor outcomes because of high malignancy, limited evidence, and scarce effective options, making personalized strategies urgent. This study evaluates precision medicine by using patient-derived tumor organoids (PTOs) as a discovery platform to explore and generate new treatment opportunities. Whole-journey clinical mapping in a neuroendocrine cervical cancer patient links longitudinal PTOs and autologous tumor-infiltrating lymphocytes (TILs) to clinical response and therapy optimization.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages21

Reading Time53 min

AccessFree to download

Abstract

Purpose

Methods

Results

Conclusion

1 Introduction

Cellular Oncology (2026) 49:48 [https://doi.org/10.1007/s13402-026-01](https://doi.org/10.1007/s13402-026-01)172-y RESEARCH Discover personalized drug opportunity and optimized tumorinfiltrating lymphocyte therapy for rare cancer: an organoid-based whole-journey clinical mapping study in a neuroendocrine cancer patient Xinyu Gao1,2 · Zhenjiang Liu3 · Zhaoting Xu1,2 · Ke Liu3 · Yiming Zhang4 · Jing Yu3 · Xu Wang3 · Xinghua Cheng5 · Chao Ni4 · Pin Wang3,6 · Yarong Liu3 · Xinfang Hong7 · Jingwei Sun3 · Bing Zhao2,4 Received: 8 November 2025 / Accepted: 31 January 2026 © The Author(s) 2026 Abstract Purpose Rare cancer patients face dire prognoses due to high malignancy and scarce treatment options, underscoring an imperative for personalized strategies. This study aims to evaluate the potential of precision medicine to extend survival in rare cancer patients by leveraging personalized tumor organoids (PTOs) as a discovery platform to comprehensively explore and generate new treatment opportunities. Methods We performed whole-journey clinical mapping in a neuroendocrine cervical cancer (NECC) patient with chemoresistant metastases. Longitudinal PTOs from three recurrent lesions and autologous tumor-infiltrating lymphocytes (TILs) were established to correlate clinical responses and discover new therapies. A co-culture system integrating PTOs and autologous TILs was developed to replicate clinical responses and optimize TIL therapy through rebuilding tumor antigen microenvironment. Results PTOs recapitulated tumor evolution and resistance imprints, enabling identification of a highly effective targeted therapy candidate post-chemotherapy failure. The co-culture system faithfully mirrored clinical immunotherapy responses, validating its potential as a companion diagnostic. Utilizing PTOs to rebuild the autologous tumor antigen microenvironment during TIL production generated a personalized, optimized TIL population. These optimized TILs exhibited enhanced anti-tumor ability and their administration correlated with clinical tumor regression in the patient. Generalizability of this PTO-based optimization strategy was validated across both patients and cancer types. Conclusion This study establishes that survival for rare cancer patients hinges on integrated, personalized companion diagnostics and therapy optimization. By bridging iterative tumor models with clinical interventions, we provide a scalable conceptual framework to overcome therapeutic nihilism and unlock precision-driven survival benefits. Keywords Whole clinical journey case study · Rare cancer · Organoids · Tumor evolution · Tumor-infiltrating lymphocyte therapy · Clinical trial · Immune co-culture 1 Introduction Globally, there are more than 200 types of rare cancers, with an annual incidence rate of approximately 6 per 100,000 as defined by the European Society For Medical Oncology | Xinyu Gao and Zhenjiang Liu contributed equally to this work. | | --- | | Bing Zhao: Lead Contact. | Extended author information available on the last page of the article (ESMO) [1] . Yet in stark contrast, rare cancers collectively account for about 20% of all cancer cases and contribute to one-fourth of cancer-related deaths, underscoring their significant overall impact [1, 2] . Patients with rare cancers often face dire prognoses [3] . For too long, their survival 1 3 needs have been neglected. The underlying reasons for this situation include: (1) profound tumor heterogeneity that complicates research, and (2) small patient populations that stymies clinical trials [4, 5] . Because rare cancers are often highly aggressive, each and every treatment opportunity for a patient is precious. However, there are scarcely any effective treatment options available for these patients [6] . In many cases, physicians are often forced to rely on case studies or borrow regimens from more common cancers with similar characteristics. Yet differences in molecular mec

FAQs

What problem does the study address for rare cancer patients?

Rare cancer patients have dire prognoses due to high malignancy, tumor heterogeneity, and limited treatment options, with small cohorts making trials difficult. The work targets the need for personalized therapies to improve clinical outcomes.

How were personalized tumor organoids and TILs used in this study?

Longitudinal PTOs from recurrent lesions and autologous tumor-infiltrating lymphocytes were established for a neuroendocrine cervical cancer case. A co-culture system combining PTOs and autologous TILs was used to replicate clinical responses and optimize TIL therapy.

What were the key findings from PTOs and the optimized TIL approach?

PTOs recapitulated tumor evolution and resistance, supporting identification of a targeted therapy candidate after chemotherapy failure. The optimized TIL population showed enhanced anti-tumor ability and was associated with clinical tumor regression, with broader validation across patients and cancer types.

Sep 22, 2026

Upload by Riley